Prasol Chemicals Q1 FY27 Investor Presentation: Strong Growth & Expansion Plans
Prasol Chemicals reported Q1 FY27 revenue of ₹433.6 crores, up 36% YoY, and EBITDA of ₹90.3 crores, up 122% YoY. Profit after tax grew 151% to ₹61.0 crores. The company plans capex of ₹500-600 crores for expansion in two phases, aiming for ₹2,800-3,000 crores revenue in five years. The company successfully listed on September 16, 2026.
The announcement details significant financial performance improvements, a successful IPO, and ambitious growth and expansion plans, which are material to investors and the company's future trajectory.
The company reported strong year-on-year growth in revenue, EBITDA, and profit after tax, alongside a positive outlook and clear expansion plans. The successful IPO listing also contributes to the positive sentiment.
Prasol Chemicals Limited has released its investor presentation for Q1 FY27, highlighting a strong start to the financial year with highest-ever quarterly performance on several key parameters. The company reported a total revenue of ₹433.6 crores, marking a 36% year-on-year growth, driven by steady volume growth, an improved product mix, and higher realisations. EBITDA surged by 122% YoY to ₹90.3 crores, with margins improving to 20.8%. This significant margin expansion was partly influenced by a ₹25 crore increase in average selling price due to geopolitical supply chain issues and ₹0.92 crore from foreign currency fluctuations, with expectations of normalisation in coming quarters. Profit after tax witnessed a substantial 151% YoY growth to ₹61.0 crores.
The company's Chairman, Mr. Nishith Shah, expressed delight in beginning their journey as a listed company following a successful IPO listing on September 16, 2026. He emphasized the strong performance in Q1 FY27, driven by better realisations, higher volumes, and an improving product mix, along with sustainable improvement in capacity utilization at the Mahad facility leading to a turnaround in profitability and an uptick in EBITDA margins. Demand for their Acetone-based and Phosphorous-based products remained healthy. The company is developing over 40 new products and plans to invest in phases to expand capabilities.
Prasol Chemicals outlined a robust expansion strategy for the next phase of growth (2026-2030). This includes a Phase I expansion focusing on existing products with a capex of approximately ₹250-300 crores over two years, aimed at debottlenecking and process augmentation. This is expected to increase revenue by ₹500-550 crores at peak utilization. Phase II expansion will target new R&D products with higher margins, involving an investment of ₹250-300 crores, with capex spending expected to begin in H2FY28. The company aspires to achieve revenues of ₹2,800-3,000 crores over the next five years, supported by industry tailwinds such as growth in the Indian Acetone Derivative and Phosphorous Derivative markets, the China + One strategy, and rising domestic consumption. Capex will be funded through internal accruals and debt.
What to do with a filing like this
Prasol Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Prasol Chemicals Limited. Read the original for the full detail.